Your Mouth's Microbiome Can Be Reprogrammed to Fight Disease

The oral microbiome is far more than a dental concern. Housing over 1,100 taxonomic groups across phyla including Firmicutes, Bacteroidetes, Proteobacteria, Fusobacteria, and Actinobacteria, the oral cavity is the body's second most complex microbial ecosystem. The Human Oral Microbiome Database catalogs core genera — Streptococcus, Veillonella, Neisseria, Actinomyces — alongside fungi such as Penicillium, Rhodotorula, and Saccharomycetales. This review, published in Folia Microbiologica (2025), synthesizes the current understanding of how microbial dysbiosis drives oral disease and how emerging microbiota-based therapies can restore balance.

Dysbiosis in the oral cavity underpins a spectrum of diseases. The 'red complex' — Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola — represents the most well-characterized pathogenic consortium, synergistically promoting periodontal destruction through virulence factors, proteolytic enzymes, and biofilm formation. Dental caries arises when acidogenic organisms like Streptococcus mutans shift the demineralization-remineralization balance toward enamel loss. Endodontic infections, oral candidiasis, and mucosal lesions each reflect distinct patterns of microbial community collapse. Critically, the review documents associations between oral dysbiosis and systemic conditions: periodontitis correlates with diabetes mellitus, cardiovascular disease, rheumatoid arthritis, and — through the proposed dental-brain axis — Alzheimer's and Parkinson's diseases.

Probiotics represent the most clinically advanced microbiota-based intervention. Streptococcus salivarius K12 and M18 strains produce bacteriocins (salivaricin A and B) that competitively inhibit S. mutans and periodontal pathogens. Multiple trials cited in the review demonstrate that Lactobacillus reuteri and Lactobacillus rhamnosus supplementation significantly reduces plaque index scores, gingival bleeding, and counts of P. gingivalis and T. forsythia. Immunological modulation is a key mechanism: probiotics downregulate pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and upregulate regulatory T-cell activity, reducing tissue destruction beyond simple competitive exclusion.

Postbiotics — bioactive compounds derived from probiotic metabolism, including short-chain fatty acids, bacteriocins, and cell wall fragments — offer the benefits of probiotics without viability requirements, conferring greater shelf stability and safety. Predatory bacteria, particularly Bdellovibrio bacteriovorus, represent a novel frontier: this organism selectively invades and lyses Gram-negative anaerobes including P. gingivalis and F. nucleatum, offering targeted elimination without broad-spectrum antibiotic collateral damage. Bacteriophages provide another precision tool, with phage cocktails demonstrating efficacy against S. mutans biofilms and periodontal pathogens in in vitro and early in vivo models. Oral microbiota transplantation (OMT), analogous to fecal microbiota transplantation, aims to reconstitute a healthy microbial community in the oral cavity of dysbiotic patients — a concept still in early experimental stages.

The review candidly addresses limitations across all these approaches. Inter-individual microbiome variability makes universal protocols difficult to establish. Most probiotic and bacteriophage studies are short-term, small-scale, or conducted in vitro, with limited long-term safety and efficacy data in humans. Regulatory frameworks for OMT and predatory bacteria remain undeveloped. Delivery system optimization — ensuring sufficient colonization of target niches like subgingival pockets — is an unresolved engineering challenge. Despite these gaps, the convergence of precision microbiology, immunology, and ecology positions microbiota-based oral therapies as a credible and necessary complement to conventional antimicrobial dentistry.